BERKELEY, Calif., Feb. 18, 2015 (GLOBE NEWSWIRE) -- XOMA Corporation (Nasdaq:XOMA), a leader in the discovery and development of therapeutic antibodies, announced today members of its management team are scheduled to present at three upcoming investor conferences. The details are as follows:
- RBC Capital Markets Global Healthcare Conference on Tuesday, February 24, 2015, at 8:00 a.m. ET
- Cowen and Company 35th Annual Health Care Conference on Wednesday, March 4, 2015, at 10:40 a.m. ET
- 27th Annual ROTH Conference on Monday, March 9, 2015, at 12:00 p.m. PT
Live audio webcasts of the presentations can be accessed through the Investors and Media section of XOMA's website at http://investors.xoma.com/events.cfm. Archived versions of the webcast will be available via replay for 60 days following the presentation.
About XOMA Corporation
XOMA's innovative product candidates are the result of the Company's expertise in developing ground-breaking monoclonal antibodies, including allosteric modulating antibodies, which has created opportunities to develop new classes of therapeutic antibodies with the potential to treat a wide range of human diseases. XOMA is developing its lead product gevokizumab (IL-1 beta modulating antibody) with SERVIER through a global Phase 3 program for Behçet's disease uveitis and non-infectious uveitis and in a Phase 3 program in pyoderma gangrenosum, as well as ongoing proof-of-concept studies in other IL-1-mediated diseases. XOMA's scientific research has also produced the XMet program, which consists of three classes of Selective Insulin Receptor Modulators (SIRMs) antibodies, including XOMA 358, that are being investigated for the treatment of abnormal metabolic states. XOMA's extensive antibody expertise includes antibody discovery, optimization, cell line and process development.
More detailed information can be found at www.xoma.com.